In contrast to our CD30 cohort, a higher number of patients (n = 34, 68%) in the CD19 group developed CRS of any grade, with 16 patients (32%) who developed grade 2 CRS and 1 patient (2%) who developed grade 3 CRS (Supplementary Table 4). The gene discussed is CD19; the disease is congenital rubella syndrome.